Literature DB >> 3319499

Cephalosporins in urinary tract infection.

L O Gentry1.   

Abstract

Despite their greater cost compared with other antibiotics, the cephalosporins continue to be used in the treatment of urinary tract infections. Most cephalosporins are excreted primarily by the kidney (by glomerular filtration, tubular secretion, or both) and urinary concentrations routinely exceed 1000 mg/L after even a small dose; exceptions include cefoperazone and ceftriaxone which both exhibit significant biliary excretion, and in patients with significant renal dysfunction only minimal concentrations of these drugs may be present in the urine. Although single-dose treatment of uncomplicated lower urinary tract infections with oral cephalosporins has not been as effective as with other antibiotics, cephalexin, cephradine and cefaclor continue to be used. Early clinical trials with cefuroxime axetil also appear promising for short term and single-dose therapy. The parenteral cephalosporins are reserved for use against more resistant strains or in hospitalised patients with upper urinary tract infections, their choice being directed by in vitro susceptibility tests. Newer agents such as ceftazidime and cefsulodin have been shown to be effective in infections due to P. aeruginosa. Recommended cephalosporin dosage regimens for the common urinary tract pathogens are given.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3319499     DOI: 10.2165/00003495-198700342-00012

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  51 in total

1.  Maternal-fetal pharmacology of cefatrizine in the first 20 weeks of pregnancy.

Authors:  B Bernard; P Thielen; J Garcia-Cázares; C A Ballard
Journal:  Antimicrob Agents Chemother       Date:  1977-08       Impact factor: 5.191

2.  Placental transfer of cephalothin.

Authors:  M A MacAulay; D Charles
Journal:  Am J Obstet Gynecol       Date:  1968-04       Impact factor: 8.661

3.  Transplacental passage of cefazolin in the first trimester of pregnancy.

Authors:  A Dekel; I Elian; Y Gibor; J A Goldman
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  1980-06       Impact factor: 2.435

4.  Treatment of urinary tract infection with a single-dose intramuscular administration of cephamandole.

Authors:  P G Shaw; K F Fairley; J A Whitworth
Journal:  Med J Aust       Date:  1980-05-17       Impact factor: 7.738

5.  Pharmacokinetics of Ro 13-9904, a broad-spectrum cephalosporin.

Authors:  M Seddon; R Wise; A P Gillett; R Livingston
Journal:  Antimicrob Agents Chemother       Date:  1980-08       Impact factor: 5.191

6.  Single-dose antimicrobial therapy for urinary tract infections in women.

Authors:  P Souney; B F Polk
Journal:  Rev Infect Dis       Date:  1982 Jan-Feb

7.  Management of acute dysuria. A decision-analysis model of alternative strategies.

Authors:  K J Carlson; A G Mulley
Journal:  Ann Intern Med       Date:  1985-02       Impact factor: 25.391

8.  Pharmacokinetics of cefoxitin in patients at term gestation: lavage versus intravenous administration.

Authors:  J F Flaherty; G W Boswell; C A Winkel; J P Elliott
Journal:  Am J Obstet Gynecol       Date:  1983-08-01       Impact factor: 8.661

9.  Ceftazidime, a new cephalosporin in the treatment of complicated urinary tract infections: a comparative study with tobramycin.

Authors:  P C Frimodt-Møller; P O Madsen
Journal:  J Urol       Date:  1983-10       Impact factor: 7.450

Review 10.  Duration of treatment of urinary tract infections.

Authors:  C M Kunin
Journal:  Am J Med       Date:  1981-11       Impact factor: 4.965

View more
  3 in total

Review 1.  Antibiotics and breast-feeding: a critical review of the literature.

Authors:  Allison M Chung; Michael D Reed; Jeffrey L Blumer
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

Review 2.  Pharmacokinetic properties of the cephalosporins.

Authors:  T Bergan
Journal:  Drugs       Date:  1987       Impact factor: 9.546

Review 3.  Contemporary management of uncomplicated urinary tract infections.

Authors:  David R P Guay
Journal:  Drugs       Date:  2008       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.